Twin Tree Management
VIR icon

Twin Tree Management’s Vir Biotechnology VIR Stock Holding History

Twin Tree Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-195
Closed -$5K – 1729
2022
Q2 		$5K Buy
195
+31
+19% +$724 ﹤0.01% 1427
2022
Q1 		$4K Buy
164
+88
+116% +$2.61K ﹤0.01% 1566
2021
Q4 		$3K Buy
+76
New +$2.98K ﹤0.01% 1532
2021
Q2 		– Sell
-4,246
Closed -$218K – 1629
2021
Q1 		$218K Buy
+4,246
New +$229K ﹤0.01% 1137

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Twin Tree Management's VIR Position: Q3 2022 in Review

Twin Tree Management sold out of Vir Biotechnology (VIR) in Q3 2022, closing a stake of 195 shares — an estimated $5K sold.

Twin Tree Management first reported a position in VIR in Q1 2021 and held it in 4 quarters. The position peaked at $218K in Q1 2021. 221 funds tracked by Wall St. Rank hold VIR as of Q3 2022.

  • Twin Tree Management reported no remaining Vir Biotechnology position as of Q3 2022 after selling out during the quarter.
  • Twin Tree Management sold 195 Vir Biotechnology shares in Q3 2022, an estimated $5K.
  • Twin Tree Management first reported a position in Vir Biotechnology in Q1 2021 and held it in 4 quarters.
  • Twin Tree Management's Vir Biotechnology position peaked at $218K in Q1 2021.
  • 221 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2022.

Based on Twin Tree Management's 13F filing for Q3 2022, filed 10 Nov 2022.